Table 3. Outcome of patients with PLA2R-related PMN.

	Remission (N = 41)		No remission (N = 21)
	n*		n*		p-value
Age at diagnosis(years)	41	51.4 [33.3; 59.3]	21	63.5 [53.9; 70.9]	0.00017
At diagnosis
Proteinuria (g/d)	41	6.0 [3.1; 10.0]	21	8.5 [5.1; 13.1]	0.0293
eGFR (mL/min)	41	87.0 [64.0; 107.0]	21	61.0 [44.0; 84.0]	0.0059
Serum albumin (g/L)	41	19.6 [15.9; 26.0]	21	21.6 [16.8; 25.6]	0.6357
PLA2R-Ab (RU/mL)	35	44.4 [0.0 ; 188.9]	17	324.2 [157.5 ; 508.3]	0.0018
PLA2R Ab serology	35		17		0.0783
Positive		25 (71.4%)		16 (94.1%)
Negative		10 (28.6%)		1 (5.9%)
PLA2R-Ag	39		19		1
Positive		37 (94.9%)		19 (100%)
Negative		2 (5.1%)		0 (0.0%)
At 6months
Proteinuria (g/d)	28	4.5 [2.4; 6.9]	15	8.0 [4.0; 13.3]	0.0350
eGFR (mL/min)	27	78.0 [56.0; 111.0]	15	33.0 [18.0; 52.0]	<0.0001
Serum albumin (g/L)	26	24.0 [20.0; 29.0]	15	22.4 [20.8; 30.0]	0.7568
PLA2R-Ab (RU/mL)	25	35.6 [0.0 ; 76.1]	8	291.2 [108.5; 606.3]	0.0035
Rituximab		15 (36.6)		7 (33.3)	P = 0.80
End of follow-up
Proteinuria (g/d)	39	0.3 [0.3; 1.4]	18	6.0 [1.0; 8.0]	< 0.0001
eGFR (mL/min)	39	80.0 [66.0; 101.0]	19	28.0 [1.0; 48.0]	< 0.0001
Serumalbumin (g/L)	38	39.0 [35.0; 41.0]	13	35.0 [23.5; 36.0]	0.0064
PLA2R –Ab (RU/mL)	33	0.0 [0.0 ; 0.0]	13	49.3 [0.0 ; 207.7]	0.0008
PLA2R- Ab serology	33		13		0.0017
Positive		6 (18.2%)		9 (69.2%)
Negative		27 (81.8)		4 (30.8%)
Ab disappearance		20/ 23 (87.0)		3/12 (25.0%)	0.0005
CKD ≥ 4	40		20		< 0.0001
Yes		0 (0.0)		13 (61.9)
No		41(100.0)		8(38.1)

* number of patients.

Frequencies (percentage) or medians (interquartile range) are shown. Quantitative variables were compared by a Student’s t-test or a Wilcoxon rank-sum test, and categorical variables were compared by a Pearson's Chi-square test or Fisher’s exact test.